Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.
Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.
Able to be present for all study procedures, complete questionnaires and assist during home data collection.
Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.
Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.
Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.
History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.
BioSensics
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Johns Hopkins University
Collaborator
Massachusetts General Hospital
Collaborator